Dr. Anna Henger
Medizinische Poliklinik
Klinische Biochemie
Schillerstr. 42
80336 München
telephone: 089-5996841
fax: 089-5996860
email: Anna.Henger@medpoli.med.uni-muenchen.de
prestype: Poster
presenter: Anna Henger
A. Henger, C. D. Cohen, D. Schlöndorff, M. Kretzler
Medizinische Poliklinik der LMU, Pettenkoferstr. 8a, 80336 München, for
the ERCB Consortium
As a consequence of the current molecular advances gene expression analysis
could become an important diagnostic tool in nephrology. The generation of a
comprehensive renal cDNA biopsy bank will be a critical pre-requisite to test
the diagnostic and prognostic value of this approach. To this end, an interdisciplinary
European collaboration of renal research centers was initiated and the following
protocol for the collection of cDNAs from microdissected renal biopsies has
been established: In participating centers informed consent is obtained from
patients undergoing routine diagnostic renal biopsy, clinical parameters are
collected in a standardized data sheet and 10% of a renal biopsy cylinder is
obtained for molecular analysis. Glomeruli and tubulo-interstitial segments
are manually microdissected and mRNA expression analysis is performed. Currently,
the biopsy material is analyzed for expression changes of candidate marker genes
with a semi-automated 'real-time' RT-PCR system. Glomerular specific cDNAs are
employed together with housekeeping mRNAs for quality control of the material
obtained. Using this system, cDNAs of interest can be reproducibly quantified
from as little as 1% of a microdissected glomerulus, enabling parallel quantification
of up to 100 different cDNAs from one biopsy segment. Microdissection effectively
separated glomeruli and tubulointerstitial compartments with no significant
cross contamination.
The ERCB will allow expression analysis in defined human renal diseases for specific cDNAs of interest. In addition, correlation of mRNA expression pattern could reveal diagnostic and prognostic molecular markers, giving nephrologists a fundamentally novel kind of information to guide their patient care. Finally, complex molecular networks activated in human renal disease processes can be identified as potential novel targets for disease management.
Members of the ERCB:
A. McKinnon, P. A. J. Brown, A. Rees, Aberdeen; P. Mertens, J. Floege, Aachen;
L. Gesualdo, F. P. Schena, Bari; M. Saleem, Bristol; M. Clarkson, H. R. Brady,
Dublin; F. Strutz, G. Müller, Göttingen; M. Kuhlmann, H. Köhler
Homburg/S.; J. K. Gerth, R. Fünfstück, G. Stein, Jena; M. P. Rastaldi,
G. D'Amico, Milan; F. Delarue, J. D. Sraer, Paris; M. Fischereder, B. Krämer,
Regensburg; R. Wütrich, St. Gallen; N. Braun, T. Risler, Tübingen;
R. Oberbauer, D. Kerjaschki, Vienna; D. Mönks, C. Wanner, Würzburg.
Abstracts * Speakers * Organizers * Home